Our group focuses on translational cancer research to ultimately improve patient outcomes. We are dedicated to advancing knowledge in two specific research fields: (i) study signaling and find potential therapeutic targets in lymphoid malignancies and (ii) to understand the impact of the microbiome in cancer patients. Our overarching objective is to elucidate the fundamental mechanisms contributing to the onset of hematologic malignancies and patients' response to established therapeutic modalities.

Our research primarily centers on the analysis of patient-derived materials, allowing us to delve into the intricacies of individual genetic and microbiomic profiles. By focusing on these personalized aspects, we aim to uncover insights that may inform more tailored and effective treatment strategies for hematologic cancers. Through rigorous investigation and collaboration, the Scheich Lab endeavors to contribute to the advancement of precision medicine and improve outcomes for patients battling these complex diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.